Log in to your Inderes Free account to see all free content on this page.
BioInvent International
38.9
SEK
+0.91 %
BINV
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
+0.91%
-15.89%
-13.94%
+18.06%
+105.17%
+119.28%
-19.46%
+40.41%
-95.92%
BioInvent International is active in the pharmaceutical industry. The company focuses on the research and development of antibody drugs used in the treatment of cancer. The company has its own development platform and collaborations take place via the company's partners. In the early development phase, the company is working to recreate the disease biology to get indications about the substance's effect on the disease. The head office is located in Lund, Sweden.
Read moreMarket cap
2.56B SEK
Turnover
3.44M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
27.2.
2025
Annual report '24
29.4.
2025
Interim report Q1'25
29.4.
2025
General meeting '24
ShowingAll content types
BioInvent announces first patient enrolled in Phase 1b/2a study of BI-1607 in combination with ipilimumab and KEYTRUDA (pembrolizumab) in patients with unresectable or metastatic melanoma
BioInvent appoints Ashley Robinson as SVP Strategy & Finance to lead US expansion
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio